<p>在全球貿易政策波動和通脹緩解的背景下，亞洲市場正在應對複雜的經濟環境。對於關注小型或新興公司的投資者來説，儘管 “便士股票” 這一術語已顯過時，但仍然在可接受的價格點上藴含增長潛力。這些股票在強勁的財務支持下可以提供顯著的價值，成為那些尋求具有良好長期前景的隱藏寶石的投資者的有趣選擇。</p>
<h3>亞洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲便士股票篩選器中的 1,161 只股票的完整列表。</p>
<p>在這裏，我們突出了一些我們篩選器中首選的股票。</p>
<h2>HighTide Therapeutics (SEHK:2511)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> HighTide Therapeutics, Inc.是一家生物製藥公司，專注於在中國大陸發現、研究、開發和商業化代謝和消化疾病的療法，市值為 14.2 億港元。</p>
<p><strong>運營：</strong> HighTide Therapeutics, Inc.目前尚未報告任何具體的收入細分。</p>
<p><strong>市值：</strong> 14.2 億港元</p>
<p>HighTide Therapeutics, Inc.是一家尚未產生收入的生物製藥公司，最近宣佈其主要化合物 HTD1801 在治療 2 型糖尿病的第三階段試驗中取得了積極結果。儘管缺乏收入且當前處於虧損狀態，但公司財務狀況良好，短期資產超過負債，現金多於債務。管理團隊經驗豐富，儘管董事會相對較新。HighTide 的股票仍然高度波動，反映出典型的便士股票特徵。即將提交的 HTD1801 新藥申請如果獲得中國監管機構的批准，可能會成為關鍵。</p>
<ul>
<li>在我們的財務健康報告中更深入地瞭解 HighTide Therapeutics 的潛力。</li>
<li>通過我們的公司歷史業績報告，獲取 HighTide Therapeutics 過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 6 月 SEHK:2511 債務與股本歷史及分析</p>
<h2>山東墨龍石油機械 (SEHK:568)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 山東墨龍石油機械有限公司及其子公司專注於能源設備產品和服務的設計、研發、生產和銷售，業務覆蓋中國及國際市場，市值為 30.6 億港元。</p>
<p><strong>運營：</strong> 山東墨龍石油機械有限公司未報告具體的收入細分。</p>
<p><strong>市值：</strong> 30.6 億港元</p>
<p>山東墨龍石油機械面臨財務挑戰與運營韌性的混合局面。儘管處於虧損狀態，但公司保持了超過三年的正現金流，得益於 20 億人民幣的短期資產超過其負債。然而，其高達 201.3% 的淨債務與股本比率和增加的債務水平突顯了財務壓力。最近的財報顯示收入有所改善，但淨收入較去年大幅下降，表明了便士股票的典型波動性。管理層缺乏經驗可能會影響他們在應對這些複雜情況時的戰略決策。</p>
<ul>
<li>在這份財務健康報告中解鎖我們對山東墨龍石油機械股票的全面分析。</li>
<li>通過我們的詳細歷史業績報告評估山東墨龍石油機械的過去業績。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 6 月 SEHK:568 收入與支出細分</p>
<h2>重慶萊美藥業 (SZSE:300006)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 重慶萊美藥業有限公司專注於在中國進行藥品的研發、生產和銷售，市值為 39.2 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入主要來自其在中國的業務，金額為 8.1287 億人民幣。</p>
<p><strong>市值：</strong> 39.2 億人民幣</p>
<p>重慶萊美藥業面臨典型便士股票的財務挑戰，儘管收入增長至 1.984 億人民幣，但 2025 年第一季度報告的淨虧損為 1378 萬人民幣。公司處於虧損狀態，但改善了其債務狀況，五年內將債務與股本比率從 74.9% 降低至 18.6%，並保持現金多於總債務，提供了超過三年的穩定現金流，即使自由現金流下降。15 億人民幣的短期資產足以覆蓋負債，儘管持續的虧損需要其經驗豐富的領導團隊進行謹慎管理，平均任期超過八年。</p>
<ul>
<li>點擊查看我們在重慶萊美藥業財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取關於重慶萊美藥業的業績記錄的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300006 截至 2025 年 6 月的收入與支出明細</p>
<h2>接下來該怎麼辦？</h2>
<ul>
<li>點擊此鏈接深入瞭解我們亞洲便士股票篩選器中的 1,161 家公司。</li>
<li>尋找替代機會？癌症的終結？這 23 只新興的人工智能股票正在開發技術，以便早期識別改變生命的疾病，如癌症和阿爾茨海默病。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

山東墨龍

萊美藥業

<p>HighTide Therapeutics 和另外兩隻亞洲便士股票在全球貿易政策波動和通脹緩解的背景下被認為是潛在的投資機會。HighTide 是一家生物製藥公司，其糖尿病治療的三期臨牀試驗結果令人鼓舞，儘管尚未產生收入。山東墨龍面臨財務挑戰，但仍保持積極的現金流。重慶萊美藥業改善了其債務狀況，但報告了淨虧損。這些股票反映了亞洲市場便士股票的波動性和潛力</p>

<p>Amidst a backdrop of fluctuating global trade policies and easing inflation, Asian markets have been navigating a complex economic landscape. For investors eyeing opportunities in smaller or newer companies, penny stocks—though an outdated term—still hold potential for growth at accessible price points. These stocks can offer notable value when backed by strong financials, making them intriguing options for those seeking hidden gems with promising long-term prospects.</p>
<div class="lb-trans"><p>在全球貿易政策波動和通脹緩解的背景下，亞洲市場正在應對複雜的經濟環境。對於關注小型或新興公司的投資者來説，儘管 “便士股票” 這一術語已顯過時，但仍然在可接受的價格點上藴含增長潛力。這些股票在強勁的財務支持下可以提供顯著的價值，成為那些尋求具有良好長期前景的隱藏寶石的投資者的有趣選擇。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亞洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1,161 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲便士股票篩選器中的 1,161 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一些我們篩選器中首選的股票。</p>
</div><h2>HighTide Therapeutics (SEHK:2511)</h2>
<div class="lb-trans"><h2>HighTide Therapeutics (SEHK:2511)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> HighTide Therapeutics, Inc. is a biopharmaceutical company focused on discovering, researching, developing, and commercializing therapies for metabolic and digestive diseases in Mainland China, with a market cap of HK$1.42 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> HighTide Therapeutics, Inc.是一家生物製藥公司，專注於在中國大陸發現、研究、開發和商業化代謝和消化疾病的療法，市值為 14.2 億港元。</p>
</div><p><strong>Operations:</strong> HighTide Therapeutics, Inc. has not reported any specific revenue segments at this time.</p>
<div class="lb-trans"><p><strong>運營：</strong> HighTide Therapeutics, Inc.目前尚未報告任何具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> HK$1.42B</p>
<div class="lb-trans"><p><strong>市值：</strong> 14.2 億港元</p>
</div><p>HighTide Therapeutics, Inc., a pre-revenue biopharmaceutical company, recently announced positive Phase 3 trial results for its lead compound HTD1801 in treating type 2 diabetes mellitus. Despite its lack of revenue and current unprofitability, the company has a strong financial position with short-term assets exceeding liabilities and more cash than debt. The management team is experienced, although the board is relatively new. HighTide's stock remains highly volatile, reflecting typical penny stock characteristics. The upcoming NDA submission for HTD1801 could be pivotal if approved by China's regulatory authorities later this year.</p>
<div class="lb-trans"><p>HighTide Therapeutics, Inc.是一家尚未產生收入的生物製藥公司，最近宣佈其主要化合物 HTD1801 在治療 2 型糖尿病的第三階段試驗中取得了積極結果。儘管缺乏收入且當前處於虧損狀態，但公司財務狀況良好，短期資產超過負債，現金多於債務。管理團隊經驗豐富，儘管董事會相對較新。HighTide 的股票仍然高度波動，反映出典型的便士股票特徵。即將提交的 HTD1801 新藥申請如果獲得中國監管機構的批准，可能會成為關鍵。</p>
</div><ul>
<li>Take a closer look at HighTide Therapeutics' potential here in our financial health report.</li>
<li>Gain insights into HighTide Therapeutics' past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更深入地瞭解 HighTide Therapeutics 的潛力。</li>
<li>通過我們的公司歷史業績報告，獲取 HighTide Therapeutics 過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2511 Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月 SEHK:2511 債務與股本歷史及分析</p>
</div><h2>Shandong Molong Petroleum Machinery (SEHK:568)</h2>
<div class="lb-trans"><h2>山東墨龍石油機械 (SEHK:568)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shandong Molong Petroleum Machinery Company Limited, along with its subsidiaries, focuses on the design, research and development, production, and sale of energy equipment products and services both in China and internationally, with a market cap of HK$3.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山東墨龍石油機械有限公司及其子公司專注於能源設備產品和服務的設計、研發、生產和銷售，業務覆蓋中國及國際市場，市值為 30.6 億港元。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for Shandong Molong Petroleum Machinery Company Limited.</p>
<div class="lb-trans"><p><strong>運營：</strong> 山東墨龍石油機械有限公司未報告具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> HK$3.06B</p>
<div class="lb-trans"><p><strong>市值：</strong> 30.6 億港元</p>
</div><p>Shandong Molong Petroleum Machinery has shown a mix of financial challenges and operational resilience. Despite being unprofitable, the company maintains a positive cash runway for over three years, supported by CN¥2 billion in short-term assets exceeding its liabilities. However, its high net debt to equity ratio of 201.3% and increased debt levels highlight financial strain. The recent earnings report shows improved revenue but a significant drop in net income compared to the previous year, indicating volatility typical of penny stocks. Management's lack of experience could impact strategic decisions as they navigate these complexities.</p>
<div class="lb-trans"><p>山東墨龍石油機械面臨財務挑戰與運營韌性的混合局面。儘管處於虧損狀態，但公司保持了超過三年的正現金流，得益於 20 億人民幣的短期資產超過其負債。然而，其高達 201.3% 的淨債務與股本比率和增加的債務水平突顯了財務壓力。最近的財報顯示收入有所改善，但淨收入較去年大幅下降，表明了便士股票的典型波動性。管理層缺乏經驗可能會影響他們在應對這些複雜情況時的戰略決策。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Shandong Molong Petroleum Machinery stock in this financial health report.</li>
<li>Assess Shandong Molong Petroleum Machinery's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份財務健康報告中解鎖我們對山東墨龍石油機械股票的全面分析。</li>
<li>通過我們的詳細歷史業績報告評估山東墨龍石油機械的過去業績。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown"/></p>
<p>SEHK:568 Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月 SEHK:568 收入與支出細分</p>
</div><h2>Chongqing Lummy Pharmaceutical (SZSE:300006)</h2>
<div class="lb-trans"><h2>重慶萊美藥業 (SZSE:300006)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Chongqing Lummy Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and sale of pharmaceutical products in China with a market cap of CN¥3.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 重慶萊美藥業有限公司專注於在中國進行藥品的研發、生產和銷售，市值為 39.2 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its operations in China, amounting to CN¥812.87 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其在中國的業務，金額為 8.1287 億人民幣。</p>
</div><p><strong>Market Cap:</strong> CN¥3.92B</p>
<div class="lb-trans"><p><strong>市值：</strong> 39.2 億人民幣</p>
</div><p>Chongqing Lummy Pharmaceutical faces financial challenges typical of penny stocks, with a net loss of CN¥13.78 million reported for Q1 2025 despite revenue growth to CN¥198.4 million. The company is unprofitable but has improved its debt profile, reducing the debt-to-equity ratio from 74.9% to 18.6% over five years and maintaining more cash than total debt, providing a stable cash runway exceeding three years even if free cash flow declines. Short-term assets of CN¥1.5 billion comfortably cover liabilities, though ongoing losses necessitate careful management by its experienced leadership team averaging over eight years in tenure.</p>
<div class="lb-trans"><p>重慶萊美藥業面臨典型便士股票的財務挑戰，儘管收入增長至 1.984 億人民幣，但 2025 年第一季度報告的淨虧損為 1378 萬人民幣。公司處於虧損狀態，但改善了其債務狀況，五年內將債務與股本比率從 74.9% 降低至 18.6%，並保持現金多於總債務，提供了超過三年的穩定現金流，即使自由現金流下降。15 億人民幣的短期資產足以覆蓋負債，儘管持續的虧損需要其經驗豐富的領導團隊進行謹慎管理，平均任期超過八年。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Chongqing Lummy Pharmaceutical's financial health report.</li>
<li>Review our historical performance report to gain insights into Chongqing Lummy Pharmaceutical's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊查看我們在重慶萊美藥業財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取關於重慶萊美藥業的業績記錄的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300006 Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>SZSE:300006 截至 2025 年 6 月的收入與支出明細</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該怎麼辦？</h2>
</div><ul>
<li>Click this link to deep-dive into the 1,161 companies within our Asian Penny Stocks screener.</li>
<li>Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們亞洲便士股票篩選器中的 1,161 家公司。</li>
<li>尋找替代機會？癌症的終結？這 23 只新興的人工智能股票正在開發技術，以便早期識別改變生命的疾病，如癌症和阿爾茨海默病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

HighTide Therapeutics 及其他兩隻亞洲低價股值得密切關注